Dsm-firmenich slips as slight Q3 beat, guidance hike 'not enough'

By Reuters News

** Shares in dsm-firmenich DSFIR.AS fall about 4%, analysts point out the Dutch ingredients maker's slight Q3 beat and FY growth outlook hike are "not enough"

** Dsm-firmenich reports Q3 adjusted EBITDA of €482 million ($541.29 million), slightly above a company-provided consensus of €478 million; it forecasts FY growth of around 5%, up from previous 2-4%

** "Is 5% enough?" Jefferies asks, expecting post-results share price pressure

** "The stock is up ~10% over the past month, suggesting expectations have moved higher; as such, an in-line print may not be enough today," J.P. Morgan says

** JPM sees implied Q4 organic sales growth of about 5% as "reassuring", but Q3-Q4 seasonality points to Q4 adjusted EBITDA in line with or slightly below consensus

($1 = 0.8905 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.